Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria.
BACKGROUND: Antimalarial drug resistance is now well established in both Plasmodium falciparum and Plasmodium vivax. In southern Papua, Indonesia, where both strains of plasmodia coexist, we have been conducting a series of studies to optimize treatment strategies. METHODS: We conducted a randomize...
| Główni autorzy: | , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Język: | English |
| Wydane: |
2007
|
| _version_ | 1826274564818075648 |
|---|---|
| author | Hasugian, A Purba, H Kenangalem, E Wuwung, R Ebsworth, E Maristela, R Penttinen, P Laihad, F Anstey, N Tjitra, E Price, R |
| author_facet | Hasugian, A Purba, H Kenangalem, E Wuwung, R Ebsworth, E Maristela, R Penttinen, P Laihad, F Anstey, N Tjitra, E Price, R |
| author_sort | Hasugian, A |
| collection | OXFORD |
| description | BACKGROUND: Antimalarial drug resistance is now well established in both Plasmodium falciparum and Plasmodium vivax. In southern Papua, Indonesia, where both strains of plasmodia coexist, we have been conducting a series of studies to optimize treatment strategies. METHODS: We conducted a randomized trial that compared the efficacy and safety of dihydroartemisinin-piperaquine (DHP) with artesunate-amodiaquine (AAQ). The primary end point was the overall cumulative parasitological failure rate at day 42. RESULTS: Of the 334 patients in the evaluable patient population, 185 were infected with P. falciparum, 80 were infected with P. vivax, and 69 were infected with both species. The overall parasitological failure rate at day 42 was 45% (95% confidence interval [CI], 36%-53%) for AAQ and 13% (95% CI, 7.2%-19%) for DHP (hazard ratio [HR], 4.3; 95% CI, 2.5-7.2; P<.001). Rates of both recrudescence of P. falciparum infection and recurrence of P. vivax infection were significantly higher after receipt of AAQ than after receipt of DHP (HR, 3.4 [95% CI, 1.2-9.4] and 4.3 [95% CI, 2.2-8.2], respectively; P<.001). By the end of the study, AAQ recipients were 2.95-fold (95% CI, 1.2- to 4.9-fold) more likely to be anemic and 14.5-fold (95% CI, 3.4- to 61-fold) more likely to have carried P. vivax gametocytes. CONCLUSIONS: DHP was more effective and better tolerated than AAQ against multidrug-resistant P. falciparum and P. vivax infections. The prolonged therapeutic effect of piperaquine delayed the time to P. falciparum reinfection, decreased the rate of recurrence of P. vivax infection, and reduced the risk of P. vivax gametocyte carriage and anemia. |
| first_indexed | 2024-03-06T22:45:22Z |
| format | Journal article |
| id | oxford-uuid:5cfc850d-6bb1-4866-a097-28f3e628fd6c |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T22:45:22Z |
| publishDate | 2007 |
| record_format | dspace |
| spelling | oxford-uuid:5cfc850d-6bb1-4866-a097-28f3e628fd6c2022-03-26T17:31:36ZDihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:5cfc850d-6bb1-4866-a097-28f3e628fd6cEnglishSymplectic Elements at Oxford2007Hasugian, APurba, HKenangalem, EWuwung, REbsworth, EMaristela, RPenttinen, PLaihad, FAnstey, NTjitra, EPrice, R BACKGROUND: Antimalarial drug resistance is now well established in both Plasmodium falciparum and Plasmodium vivax. In southern Papua, Indonesia, where both strains of plasmodia coexist, we have been conducting a series of studies to optimize treatment strategies. METHODS: We conducted a randomized trial that compared the efficacy and safety of dihydroartemisinin-piperaquine (DHP) with artesunate-amodiaquine (AAQ). The primary end point was the overall cumulative parasitological failure rate at day 42. RESULTS: Of the 334 patients in the evaluable patient population, 185 were infected with P. falciparum, 80 were infected with P. vivax, and 69 were infected with both species. The overall parasitological failure rate at day 42 was 45% (95% confidence interval [CI], 36%-53%) for AAQ and 13% (95% CI, 7.2%-19%) for DHP (hazard ratio [HR], 4.3; 95% CI, 2.5-7.2; P<.001). Rates of both recrudescence of P. falciparum infection and recurrence of P. vivax infection were significantly higher after receipt of AAQ than after receipt of DHP (HR, 3.4 [95% CI, 1.2-9.4] and 4.3 [95% CI, 2.2-8.2], respectively; P<.001). By the end of the study, AAQ recipients were 2.95-fold (95% CI, 1.2- to 4.9-fold) more likely to be anemic and 14.5-fold (95% CI, 3.4- to 61-fold) more likely to have carried P. vivax gametocytes. CONCLUSIONS: DHP was more effective and better tolerated than AAQ against multidrug-resistant P. falciparum and P. vivax infections. The prolonged therapeutic effect of piperaquine delayed the time to P. falciparum reinfection, decreased the rate of recurrence of P. vivax infection, and reduced the risk of P. vivax gametocyte carriage and anemia. |
| spellingShingle | Hasugian, A Purba, H Kenangalem, E Wuwung, R Ebsworth, E Maristela, R Penttinen, P Laihad, F Anstey, N Tjitra, E Price, R Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. |
| title | Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. |
| title_full | Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. |
| title_fullStr | Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. |
| title_full_unstemmed | Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. |
| title_short | Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. |
| title_sort | dihydroartemisinin piperaquine versus artesunate amodiaquine superior efficacy and posttreatment prophylaxis against multidrug resistant plasmodium falciparum and plasmodium vivax malaria |
| work_keys_str_mv | AT hasugiana dihydroartemisininpiperaquineversusartesunateamodiaquinesuperiorefficacyandposttreatmentprophylaxisagainstmultidrugresistantplasmodiumfalciparumandplasmodiumvivaxmalaria AT purbah dihydroartemisininpiperaquineversusartesunateamodiaquinesuperiorefficacyandposttreatmentprophylaxisagainstmultidrugresistantplasmodiumfalciparumandplasmodiumvivaxmalaria AT kenangaleme dihydroartemisininpiperaquineversusartesunateamodiaquinesuperiorefficacyandposttreatmentprophylaxisagainstmultidrugresistantplasmodiumfalciparumandplasmodiumvivaxmalaria AT wuwungr dihydroartemisininpiperaquineversusartesunateamodiaquinesuperiorefficacyandposttreatmentprophylaxisagainstmultidrugresistantplasmodiumfalciparumandplasmodiumvivaxmalaria AT ebsworthe dihydroartemisininpiperaquineversusartesunateamodiaquinesuperiorefficacyandposttreatmentprophylaxisagainstmultidrugresistantplasmodiumfalciparumandplasmodiumvivaxmalaria AT maristelar dihydroartemisininpiperaquineversusartesunateamodiaquinesuperiorefficacyandposttreatmentprophylaxisagainstmultidrugresistantplasmodiumfalciparumandplasmodiumvivaxmalaria AT penttinenp dihydroartemisininpiperaquineversusartesunateamodiaquinesuperiorefficacyandposttreatmentprophylaxisagainstmultidrugresistantplasmodiumfalciparumandplasmodiumvivaxmalaria AT laihadf dihydroartemisininpiperaquineversusartesunateamodiaquinesuperiorefficacyandposttreatmentprophylaxisagainstmultidrugresistantplasmodiumfalciparumandplasmodiumvivaxmalaria AT ansteyn dihydroartemisininpiperaquineversusartesunateamodiaquinesuperiorefficacyandposttreatmentprophylaxisagainstmultidrugresistantplasmodiumfalciparumandplasmodiumvivaxmalaria AT tjitrae dihydroartemisininpiperaquineversusartesunateamodiaquinesuperiorefficacyandposttreatmentprophylaxisagainstmultidrugresistantplasmodiumfalciparumandplasmodiumvivaxmalaria AT pricer dihydroartemisininpiperaquineversusartesunateamodiaquinesuperiorefficacyandposttreatmentprophylaxisagainstmultidrugresistantplasmodiumfalciparumandplasmodiumvivaxmalaria |